Phase I study of RAD001 (Everolimus) in combination with Fluvastatin and Zoledronic acid in patients with solid tumours

This study aims to investigate whether the combination of everolimus (RAD001), fluvastatin, and zoledronic acid can be given safely together and to determine the toxicities, if any, of the combination. Who is it for? You may be eligible for this study if you have advanced cancer which has continued to grow despite the use of other therapies. Trial Details In this trial, you will receive an combined treatment of the drugs Everolimus escalating from 2.5mg to 10mg daily, fluvastatin 80mg to 120mg daily, and zoledronic acid 4mg intravenously every 3 weeks until either you experience intolerable side effects or until your cancer grows again. We hope that the combination treatment will ultimately not only be fairly well tolerated, but act synergistically to help slow down the rate of tumour growth.